— Know what they know.
Not Investment Advice

PVCT Smart Money

Provectus Biopharmaceuticals, Inc.
1W: -2.7% 1M: -15.1% 3M: -21.7% YTD: -23.9% 1Y: -33.9% 3Y: -25.3% 5Y: -21.7%
$0.05
-0.00 (-0.41%)
 
Weekly Expected Move ±7.6%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 36 · $20.4M mcap · 389M float · 0.037% daily turnover · Short 18% of daily vol
Credit Risk of going bust: higher than 81% of companies Debt: 14.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 95%), Provectus Biopharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $3.5M against a stock market value of $20.4M.
Distance to default 2.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 80.5%; Altman Z'' -634.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

🏦 Institutional Activity

Latest: Q2 2026
4
Institutions Holding
+0 vs prior
0.0%
Ownership
-0.00%
0 New
0 Increased
1 Reduced
1 Closed

👔 Insider Trades

0 records
Date Name Title Type Shares Price Value Filing
No insider trades found

🏛️ Congressional Trades

0 records
Date Politician Chamber Type Amount Filing
No congressional trades found

🏦 Top Institutional Holders

4 holders
Holder Shares Value Date Reported Filing
HOME FEDERAL BANK OF TENNESSEE 100,000 $7K — 2026-06-30 Filing
Atlas Wealth LLC 19,620 $1K — 2026-06-30 Filing
Financial Symmetry Inc 10,191 $1K — 2026-06-30 Filing
Wealth Preservation Advisors, LLC 0 $0K -52,600 2026-06-30 Filing

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms